NANOPATHDX, INC.

Medtech · Private

Point-of-care molecular diagnostic assay cartridge with integrated nanosensor for rapid UTI pathogen and antibiotic resistance identification from urine

Grants
$2.0M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Multiplexed Assay for Point-of-Care UTI Diagnosis (ID/AMR)$996,726
Federal grantDepartment of Health and Human Services · Phase II · Multiplexed Assay for Point-of-Care UTI Diagnosis (ID/AMR)$964,943
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1894Looking Glass Productions, LLC—$125K
1895REQUISITE BIOMEDICAL, LLC——
1896POWERSCOPE, INC——
1897NANOPATHDX, INC.——
1898QATCH TECHNOLOGIES LLC——
1899VISO Therapeutics Inc.——
1900ORB XYZ, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.